Year All20242023202220212020201920182017201620152014 Abivax late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021 September 28, 2021 Read More Abivax presents first-half 2021 financial results and operations update September 23, 2021 Read More Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis September 14, 2021 Read More Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis August 17, 2021 Read More Abivax publishes a prospectus in the context of its capital increase and bonds offering July 23, 2021 Read More Abivax announces the pricing of its oversubscribed capital increase of EUR 60M and convertible bonds of EUR 25M, totaling EUR 85M new financing July 23, 2021 Read More Abivax announces a capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80M July 22, 2021 Read More Company statement: Jean-Marc Steens, M.D., decides to end his career at Abivax July 02, 2021 Read More Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis June 23, 2021 Read More Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting June 07, 2021 Read More
Abivax late-breaking abstract presentation and Live Industry Symposium at UEG Week Virtual 2021 September 28, 2021 Read More
Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis September 14, 2021 Read More
Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis August 17, 2021 Read More
Abivax publishes a prospectus in the context of its capital increase and bonds offering July 23, 2021 Read More
Abivax announces the pricing of its oversubscribed capital increase of EUR 60M and convertible bonds of EUR 25M, totaling EUR 85M new financing July 23, 2021 Read More
Abivax announces a capital increase and convertible bonds issue to qualified investors for an aggregate amount of approximately EUR 80M July 22, 2021 Read More
Company statement: Jean-Marc Steens, M.D., decides to end his career at Abivax July 02, 2021 Read More
Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis June 23, 2021 Read More
Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting June 07, 2021 Read More
